研究单位:[1]Shanghai Biomabs Pharmaceutical Co., Ltd.[2]Beijing Tongren Hospital,Beijing,China,100730[3]Peking University People'S Hospital,Beijing,China,100044[4]Renmin Hospital of Wuhan University,Wuhan,Hubei,China,430060[5]Shanghai General Hospital,Shanghai,Shanghai,China,200080
研究目的:
This is a randomized, double-blind, two-group parallel, positive-controlled clinical Phase I trial comparing the safety, pharmacokinetics, pharmacodynamics and efficacy of CMAB818 and Lucentis® in patients with wet age-related macular degeneration.